Table 2.

Summary of clinical features

Patient	Age	Malignancy (stage)	Chemotherapy regimens (purpose if available)	Associated medical problems	Gynecologic symptoms	Interval from chemotherapy to curettage	Hysteroscopic findings	Current status	Follow-up period
1	63	Uterine cervical cancer (FIGO IIB)	Paclitaxel, cisplatin, ifosfamide	Septic shock, neutropenia	Vaginal bleeding	4 months	Atrophic endometrium	NED	54 months
2	39	Rectal cancer (cT4N+M0/ypT0N0M0)	Capecitabine (NAC)	None	Vaginal bleeding	2 months	Atrophic endometrium	NED	12 months
3	42	Rectal cancer (cT3N+M0/ypT3N1aM0)	Capecitabine (NAC); FOLFOX, FOLFIRI, etoposide, ifosfamide (palliative)	None	Vaginal bleeding	10 months	Atrophic endometrium	NED	17 months
4	52	Myelodysplastic syndrome (RAEB-2)	Decitabine; cyclophosphamide, busulfan (conditioning)	PBSCT, CMV viremia, IUD in situ	Vaginal bleeding	4 months	Atrophic endometrium	NED	4 months

NED: no evidence of endometrial disease; NAC: neoadjuvant chemotherapy; FOLFOX: leucovorin, 5-fluorouracil and oxaliplatin; FOLFIRI: leucovorin, 5-fluorouracil and irinotecan; RAEB: refractory anemia with excess blasts; PBSCT: allogeneic peripheral blood stem cell transplantation; CMV: cytomegalovirus; IUD: intrauterine device.